ETFs & Funds
Home›ETFs & Funds›ETFs›LABU pulls in $266 million as biotech M&A fuels ETF re…
LABU pulls in $266 million as biotech M&A fuels ETF rebound
The Direxion Daily S&P Biotech Bull 3x Shares ETF is up 52.5% year to date and has surged 118% over 12 months, while total pharma deal value reaches $216 billion in 2026, nearly double 2025’s $118 billion.
Biotechnology stocks are showing signs of recovery as pharmaceutical mergers and acquisitions pick up, and ETF Trends highlights the Direxion Daily S&P Biotech Bull 3x Shares (LABU) as one fund benefiting from the move.
According to ETF Trends, LABU pulled in $266 million over the past week, even though its reference index has been down for that period. The article also says LABU is up 52.5% year to date and about 118% over the past 12 months, with a 0.96% expense ratio.
ETF Trends reports that LABU tracks the S&P Biotechnology Select Industry Index and is designed to deliver triple the daily performance of that benchmark. The outlet links the potential upswing in biotech to a surge in large pharma deals, noting drugmakers have announced 37 biotech company purchases worth at least $1 billion each this year so far.
The article adds that total transaction value has reached $216 billion in 2026, nearly doubling from $118 billion the previous year, as big acquisitions aim to offset revenue pressure tied to upcoming patent expirations.